158461-46-2

Basic information

• Product Name: Benzenamine, 2-(2-pyridinyl)-5-(trifluoromethyl)-
• CAS NO: 158461-46-2
• Molecular Formula: C12H9F3N2
• Molecular Weight: 238.212
• Mol File: 158461-46-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Benzenamine, 2-(2-pyridinyl)-5-(trifluoromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 2-(2-pyridinyl)-5-(trifluoromethyl)-(158461-46-2)
• EPA Substance Registry System: Benzenamine, 2-(2-pyridinyl)-5-(trifluoromethyl)-(158461-46-2)

Safety Data

• Hazardous Substances Data: 158461-46-2(Hazardous Substances Data)

Upstream product

• 454-79-5 2-Bromo-5-trifluoromethylaniline 
• 109-04-6 2-bromo-pyridine 
• 1196972-92-5 5-(trifluoromethyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenamine 
• 17997-47-6 2-tri-n-butylstannylpyridine 
• 400-98-6 4-trifluoromethyl-2-nitroaniline 
• 110-86-1 pyridine 
• 158461-30-4 2-(2-Nitro-4-trifluoromethyl-phenyl)-pyridine 

Downstream Products

• 1045866-35-0 13-methyl-2,14-dioxo-17 (2-(pyridin-2-yl)-5-trifluoromethylphenylcarbamoyloxy)-3,13-diazatricyclo[13.3.0.0^4,6]octadec-7-ene-4-carboxylic acid ethyl ester 
• 158461-70-2 [1-Methyl-2-(2-pyridin-2-yl-5-trifluoromethyl-phenylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester 
• 1393606-44-4 1-methyl-2-(2-azido-4-trifluoromethylphenyl)pyridinium triflate 
• 1393606-85-3 2-(2-azido-4-trifluoromethylphenyl)pyridine 

Relevant articles and documents

ERAP1 MODULATORS

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, A compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, (I) wherein: Z is a group of formula: (II) wherein P

RhII2-catalyzed synthesis of α-, β-, or δ-carbolines from aryl azides

Approaching all isomers: A range of α-, β- and δ-carbolinium ions are readily available from ortho-substituted aryl azides using a rhodium(II) carboxylate catalyst (see scheme). The carbolinium ions are readily reduced to afford tryptolines or deprotonated to access pyridoindoles. This [RhII2]-catalyzed C-H bond amination was used in the synthesis of (±)-horsfiline and neocryptolepine. esp=α,α,α',α'- tetramethyl-1,3-benzenedipropionate. Copyright

MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by ------) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is -OR6, -NH-SO2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 independently from one another are hydrogen, halo, hydroxy, nitro, cyano, carboxyl, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkylcarbonyl, C1-6alkoxy- carbonyl, amino, azido, mercapto, C1-6alkylthio, polyhaloC1-6alkyl, aryl or Het; W is aryl or Het; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 - 4 heteroatoms each independently selected from N, O or S, and optionally substituted with 1 -3 substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.